Skip to content

20- Versus 23- Gauge System for Pars Plana Vitrectomy

20- Versus 23- Gauge System for Pars Plana Vitrectomy: A Prospective Randomized Clinical Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00411970
Enrollment
60
Registered
2006-12-15
Start date
2004-09-30
Completion date
2007-10-31
Last updated
2007-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy, Macular Edema, Postoperative Complications, Vitreous Hemorrhage

Keywords

23 gauge pars plana vitrectomy, conjunctival erythema and injection, 20 gauge pars plana vitrectomy, vitreous and retinal surgery

Brief summary

The aim of the present study is to compare the functional and clinical differences and advantages between a standard operating system and a newly developed even smaller system for pars plana vitrectomy. The present study may work out the possible advantages and disadvantages between the routinely used 20-gauge vitrectomy system and the newly developed 23-gauge device.

Detailed description

60 patient randomized into 2 groups of 30 each. All of them operated in general anesthesia, vitrectomized and cataract extracted by phacoemulsification if indicated. Preoperative and postoper5ative controls at days 1,2,3 and week 1, month 1,3 and 12 performed. Parameters of interest are: postoperative conjunctival injection, pain, eye pressure, complications intra- and postoperative as well as the durations of surgery divided into opening time, vitrectomy time, retinal manipulation time, closing time.

Interventions

DEVICE20- and 23 gauge vitreoretinal surgery systems

Sponsors

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Over 18 years of age * Written form of consent * Vitreous and retinal pathologies requiring surgery

Exclusion criteria

* Previous history of vitreous or retinal surgery * Pregnant or breastfeeding women * Prohibiting general medical conditions or diseases * No informed consent signed * Under 18 years of age

Design outcomes

Primary

MeasureTime frame
Conjunctival Injection
Subjective postoperative recovery

Secondary

MeasureTime frame
Visual acuity
Surgery time
Intra- and postoperative complications
Technically successful surgery (from surgeon's view)
Intraocular pressure

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026